Concepedia

Nils Rettby

NR

Statistics

Publications

6

Citations

365

H-Index

6

Active since

2015

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

Tokyo National Hospital

University Hospital of Lausanne

Nils Rettby is an author at Bristol-Myers Squibb (Switzerland) specializing in vaccinology, immunization, and immunology.

ORCID

Publications per year

2015–2022

6

Publications

6

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

François Spertini, R Audran, Reza Chakour et al. · The Lancet Respiratory Medicine · 2015 · 175 citations · Full text

, , +13

Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial

Matteo Mombelli, Nils Rettby, Matthieu Perreau et al. · Vaccine · 2018 · 55 citations

, , +13

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

Giuseppe Pantaleo, Holly Janes, Shelly Karuna et al. · The Lancet HIV · 2019 · 50 citations · Full text

, , +17

Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™

Paul Vescovo, Nils Rettby, Nirinarilala Ramaniraka et al. · Vaccine · 2017 · 40 citations · Full text

, , +17

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell <scp>non‐Hodgkin</scp> lymphoma

Shinichi Makita, Go Yamamoto, Dai Maruyama et al. · Cancer Medicine · 2022 · 28 citations · Full text

, , +17

1–5 of 6